Biofrontera AG - 30 Jun 2025 Form 3 Insider Report for Biofrontera Inc. (BFRI)

Reporting relationship: Director
Issuer ticker: BFRI
Reported as of: 30 Jun 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 09 Jul 2025, 14:56:55 UTC
Prior SEC filing: 28 Oct 2021
Next SEC filing: 18 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Pilar de la Huerta, as Chief Financial Officer of Biofrontera AG

Key filing fact

Biofrontera AG filed Form 3 for Biofrontera Inc. (BFRI) on 09 Jul 2025.

Key facts

This page summarizes Biofrontera AG's Form 3 filing for Biofrontera Inc. (BFRI).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Jul 2025, 14:56.

Change

Previous filing in this sequence was filed on 28 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712641 Primary reporting owner

Biofrontera AG

Relationship: Director
Address: HEMMELRATHER WEG 201, LEVERKUSEN, GERMANY
Signature: /s/ Pilar de la Huerta, as Chief Financial Officer of Biofrontera AG
Signature date: 09 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BFRI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 400,000
Date: 30 Jun 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

On June 30, 2025, the Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.